Therefore, IV iron represents a potentially safer and more sustainable therapeutic alternative for this patient population.Despite this clinical need, the efficacy of IV iron monotherapy in patients with more severe chemotherapy-induced anemia (CIA) (Hb <10 g/dL) has not been adequately established. The gene discussed is GSTM1; the disease is anemia.